Jesse Nussbaum, MD
Assistant Professor
Medicine
School of Medicine

Education & Training

Show all (1) Hide

• M.D. School of Medicine Duke University 2004

Websites

Show all (2) Hide

• Profile at id.medicine.ucsf.edu (id.medicine.ucsf.edu)
• Clinical profile at UCSF Medical Center (ucsfhealth.org)

Grants and Projects

Show all (1) Hide

• Interaction between innate and Th2 lymphocytes in helminth immunity, NIH, 2014-2019

Publications (34)

Top publication keywords:
PyrimethamineReceptors, Purinergic P2X3Meningitis, CryptococcalCoughPurinergic P2X Receptor AntagonistsSulfonamidesPyrimidinesEosinophilsImmunity, InnateFlucytosineLymphocytesCell SeparationRenal InsufficiencyHealthy VolunteersFluconazole

• Gefapixant as a P2X3 receptor antagonist treatment for obstructive sleep apnea: a randomized controlled trial.
  Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2024 Robbins JA, Sands S, Maganti L, Crumley T, Fox-Bosetti S, Hussain A, Schwartz H, Safirstein B, Ahmad M, Dragone L, Nussbaum J, Kushida C, Iwamoto M, Stoch SA
• Single- and Multiple-Dose Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist, in Healthy Adults.
  Journal of clinical pharmacology 2024 Nussbaum JC, Hussain A, Butera P, Ford AP, Kitt MM, O'Neill EA, Smith S, Vargas G, O'Reilly T, Wynne C, Stoch SA, Iwamoto M
• Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults.
  Vaccine 2023 Nussbaum J, Cao X, Railkar RA, Sachs JR, Spellman DS, Luk J, Shaw CA, Cejas PJ, Citron MP, Al-Ibrahim M, Han D, Pagnussat S, Stoch SA, Lai E, Bett AJ, Espeseth AS
• Considerations for Cell and Gene Therapy Programs Entering the Clinical Space.
  Clinical pharmacology and therapeutics 2023 Walford GA, Bautmans A, Cannon C, Duncan KE, Deschamps K, Matthews RP, Nussbaum J, Stoch SA
• Population pharmacokinetic analysis of the P2X3-receptor antagonist gefapixant.
  CPT: pharmacometrics & systems pharmacology 2023 Chawla A, Largajolli A, Hussain A, Kleijn H, Ait-Oudhia S, Anton J, Krishna Ananthula H, Nussbaum J, La Rosa C, Gheyas F

Show all (29 more) Hide

• Transition of care in inborn errors of immunity: Outcomes of a single-center quality improvement initiative.
  The journal of allergy and clinical immunology. In practice 2023 Sanchez LA, Tang M, Ahmed A, Nussbaum JC, Nguyen DN, Muskat M, Chen XH, Pham MN
• International consortium for innovation and quality: An industry perspective on the nonclinical and early clinical development of intravitreal drugs.
  Clinical and translational science 2023 Pruimboom-Brees IM, Gupta S, Chemuturi N, Booler HS, Nimz E, Ferrell Ramos M, Caruso A, Maass KF, Bantseev V, Huang Q, Choules MP, Nussbaum JC, Kanodia J, Thompson C, Durairaj C
• Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist.
  Journal of clinical pharmacology 2022 Nussbaum JC, Hussain A, Min KC, Marbury TC, Lasseter K, Stoch SA, Iwamoto M
• A Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 3 Weeks of Orally Administered Gefapixant in Healthy Younger and Older Adults.
  Lung 2022 Nussbaum J, Hussain A, Ford A, Butera P, Kitt M, Smith S, Stoch A, Iwamoto M
• Clinical Formulation Bridging of Gefapixant, a P2X3-Receptor Antagonist, for the Treatment of Chronic Cough.
  Clinical pharmacology in drug development 2022 Gupta P, Hussain A, Ford AP, Smith S, Nussbaum JC, Stoch A, Iwamoto M
• Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans.
  Pharmacology research & perspectives 2022 Nussbaum JC, Hussain A, Ma B, Min KC, Chen Q, Tomek C, Iwamoto M, Stoch SA
• Assessment of the Effect of Pyrimethamine, a Potent Inhibitor of Multidrug and Toxin Extrusion Protein 1/2K, on the Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist.
  Clinical pharmacology in drug development 2021 Nussbaum JC, Hussain A, Ma B, Min KC, Evers R, Li Y, Garrett G, Stoch SA, Iwamoto M
• Tissue-Resident Group 2 Innate Lymphoid Cells Differentiate by Layered Ontogeny and In Situ Perinatal Priming.
  Immunity 2019 Schneider C, Lee J, Koga S, Ricardo-Gonzalez RR, Nussbaum JC, Smith LK, Villeda SA, Liang HE, Locksley RM
• Tissue signals imprint ILC2 identity with anticipatory function.
  Nature immunology 2018 Ricardo-Gonzalez RR, Van Dyken SJ, Schneider C, Lee J, Nussbaum JC, Liang HE, Vaka D, Eckalbar WL, Molofsky AB, Erle DJ, Locksley RM
• 1021 Origin of type 2 innate lymphoid cells in the skin.
  Journal of Investigative Dermatology 2018 J. Lee, C. Schneider, H. Liang, R. Ricardo-Gonzalez, J. Nussbaum, L. Smith, S. Villeda, R. Locksley
• Isolation and Identification of Group 2 Innate Lymphoid Cells in Settings of Type 2 Inflammation.
  Methods in molecular biology (Clifton, N.J.) 2018 Nussbaum JC, Ortiz-Carpena JF
• LB973 Characterization of tissue-resident ILC2 heterogeneity in homeostasis.
  Journal of Investigative Dermatology 2017 R. Ricardo-Gonzalez, S. Van Dyken, A. Molofsky, J. Nussbaum, J. Lee, R. Locksley
• A tissue checkpoint regulates type 2 immunity.
  Nature immunology 2016 Van Dyken SJ, Nussbaum JC, Lee J, Molofsky AB, Liang HE, Pollack JL, Gate RE, Haliburton GE, Ye CJ, Marson A, Erle DJ, Locksley RM
• A Case of Hypercalcemia and Overexpression of CYP27B1 in Skeletal Muscle Lesions in a Patient with HIV Infection After Cosmetic Injections with Polymethylmethacrylate (PMMA) for Wasting.
  Calcified tissue international 2015 Hindi SM, Wang Y, Jones KD, Nussbaum JC, Chang Y, Masharani U, Bikle D, Shoback DM, Hsiao EC
• Group 2 innate lymphoid cells utilize the IRF4-IL-9 module to coordinate epithelial cell maintenance of lung homeostasis.
  Mucosal immunology 2015 Mohapatra A, Van Dyken SJ, Schneider C, Nussbaum JC, Liang HE, Locksley RM
• Interleukin-33 and Interferon-γ Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune Perturbation.
  Immunity 2015 Molofsky AB, Van Gool F, Liang HE, Van Dyken SJ, Nussbaum JC, Lee J, Bluestone JA, Locksley RM
• Activated type 2 innate lymphoid cells regulate beige fat biogenesis.
  Cell 2014 Lee MW, Odegaard JI, Mukundan L, Qiu Y, Molofsky AB, Nussbaum JC, Yun K, Locksley RM, Chawla A
• Chitin activates parallel immune modules that direct distinct inflammatory responses via innate lymphoid type 2 and γδ T cells.
  Immunity 2014 Van Dyken SJ, Mohapatra A, Nussbaum JC, Molofsky AB, Thornton EE, Ziegler SF, McKenzie AN, Krummel MF, Liang HE, Locksley RM
• Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013 Jarvis JN, Bicanic T, Loyse A, Namarika D, Jackson A, Nussbaum JC, Longley N, Muzoora C, Phulusa J, Taseera K, Kanyembe C, Wilson D, Hosseinipour MC, Brouwer AE, Limmathurotsakul D, White N, van der …
• Type 2 innate lymphoid cells control eosinophil homeostasis.
  Nature 2013 Nussbaum JC, Van Dyken SJ, von Moltke J, Cheng LE, Mohapatra A, Molofsky AB, Thornton EE, Krummel MF, Chawla A, Liang HE, Locksley RM
• 265 Cooperative activation of innate lymphoid type 2 cells (ILC2) by epithelial cytokines in response to chitin.
  Cytokine 2013 Steven J. Van Dyken, Alexander Mohapatra, Jesse C. Nussbaum, Hong-Erh Liang, Richard M. Locksley
• Type 2 innate lymphoid cells constitutively express arginase-I in the naive and inflamed lung.
  Journal of leukocyte biology 2013 Bando JK, Nussbaum JC, Liang HE, Locksley RM
• Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages.
  The Journal of experimental medicine 2013 Molofsky AB, Nussbaum JC, Liang HE, Van Dyken SJ, Cheng LE, Mohapatra A, Chawla A, Locksley RM
• A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis.
  AIDS (London, England) 2012 Jackson AT, Nussbaum JC, Phulusa J, Namarika D, Chikasema M, Kanyemba C, Jarvis JN, Jaffar S, Hosseinipour MC, van der Horst C, Harrison TS
• Infectious (Non)tolerance--frustrated commensalism gone awry?
  Cold Spring Harbor perspectives in biology 2012 Nussbaum JC, Locksley RM
• Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010 Nussbaum JC, Jackson A, Namarika D, Phulusa J, Kenala J, Kanyemba C, Jarvis JN, Jaffar S, Hosseinipour MC, Kamwendo D, van der Horst CM, Harrison TS
• Cryptococcus neoformans virulence gene discovery through insertional mutagenesis.
  Eukaryotic cell 2004 Idnurm A, Reedy JL, Nussbaum JC, Heitman J
• Enzymes that counteract nitrosative stress promote fungal virulence.
  Current biology : CB 2003 de Jesús-Berríos M, Liu L, Nussbaum JC, Cox GM, Stamler JS, Heitman J
• 2006 expressed-sequence tags derived from human chromosome 7-enriched cDNA libraries.
  Genome research 1997 Touchman JW, Bouffard GG, Weintraub LA, Idol JR, Wang L, Robbins CM, Nussbaum JC, Lovett M, Green ED